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Purpose. Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenaﬁl
for the treatment of neuropathic pain. The focus of this study was to determine the inﬂuence of sildenaﬁl
on the pharmacokinetics (PK) of pregabalin with the objective of informing the design of a quantitative
pharmacodynamic (PD) study.
Methods. The pharmacokinetics were determined in rats following 2-hr intravenous infusions of
pregabalin at doses of 4 mg/kg/hr and 10 mg/kg/hr with and without a sildenaﬁl bolus (2.2 mg) and
steady state infusion (12 mg/kg/hr for 6 h). This PK model was utilized in a preclinical trial simulation
with the aim of selecting the optimal sampling strategy to characterize the PK-PD proﬁle in a future
study. Eight logistically feasible PK sampling strategies were simulated in NONMEM and examined
through trial simulation techniques.
Results. A two-compartment population PK model best described pregabalin pharmacokinetics.
Signiﬁcant model covariates included either a binary effect of sildenaﬁl administration (30.2% decrease
in clearance) or a concentration-dependent effect due to sildenaﬁl’s active metabolite.
Conclusions. Analysis of simulations indicated that three post-PD samples had the best cost/beneﬁt ratio
by providing a signiﬁcant increase in the precision (and minor improvement in bias) of both PK and PD
parameters compared with no PK sampling.
KEY WORDS: neuropathic pain; optimal sampling; synergistic interaction; trial simulation.
INTRODUCTION
Neuropathic pain represents an area of largely unmet
medical need, with signiﬁcant impact on health-related
quality of life (1). At present, neuropathic pain is treated
with a variety of different medications with various mecha-
nisms of action (2–7). Current treatments for neuropathic
pain achieve some relief from the unrelenting pain, leaving
signiﬁcant room for improvement (8). An intriguing question
is whether a greater effectiveness can be obtained by using
rational combinations of drugs (9, 10). The optimization of a
rational drug combination represents a major challenge (11).
Pharmacokinetic-pharmacodynamic (PK-PD) modeling
has been recognized as a promising tool for preclinical drug
development including rational drug combinations (12, 13). In
investigations on PD interactions, it is important to ﬁrst account
for any potential PK interactions (14, 15). The characterization
of PK in pre-clinical PD investigations is not without complica-
tions,as bloodsampling may interferewith behavioralmeasure-
ments. This may require the application of innovative study
designs and data-analysis techniques (16–18).
Pregabalin exhibits its activity as a ligand to the α2δ
subunit of the voltage gated calcium channel (VGCC). Avid
binding at this site reduces calcium inﬂux at nerve terminals
and therefore reduces the release of several neurotransmit-
ters including glutamate, norepinepherine and substance P
(19). It has been demonstrated to exhibit anti-allodynic (20,
21), anxiolytic (22, 23) and anticonvulsant (24) activity.
Sildenaﬁl is a potent and selective Phosphodiesterase
type 5 (PDE-5) inhibitor. PDE-5 is an enzyme primarily
responsible for the breakdown of cGMP, an intracellular
second messenger. As the breakdown of cGMP is inhibited,
increased intracellular concentrations of cGMP result and are
thought to be primarily responsible for its therapeutic activity.
It was originally investigated to treat angina, but its current
therapeutic indication is in the treatment of male erectile
dysfunction (25). Due to the prevalence of PDE-5 in many
systems in the body, sildenaﬁl has also been successfully
applied for the treatment of other conditions, including
pulmonary hypertension (26, 27). Recently, it has been
observed that sildenaﬁl enhances the effects of pregabalin in
an animal model of neuropathic pain (28). While the
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sildenaﬁl may exhibit a PD synergistic interaction with
pregabalin by increasing intracellular concentrations of
cGMP. In turn, increased intracellular cGMP may amplify
downstream regulation of the VGCC and modify pain
perception in neuropathic pain.
The scope of this paper is to describe the development of
a PK model identifying any potential PK interaction between
pregabalin and sildenaﬁl in rats with the objective of
informing the design of a future quantitative PD study
examining this interaction. Furthermore, the ultimate goal is
the translation of this interaction to guide the ﬁrst inves-
tigations of this drug combination in humans (29).
The overall process of informing the PD study design is
outlined in Fig. 1. First, a PK study is conducted and a PK
model developed using data collected from that study. This
PK model provides the basis for investigating optimal PK
sampling strategies for a PD study where PK sampling is not
possible during the PD experiment. The necessity of design-
ing the PK sampling in this way was demonstrated by a
decrease in precision of PD endpoints during pilot studies
where blood sampling was conducted in a chronic constriction
injury rat model of neuropathic pain (Bender et al., unpub-
lished). This distortion required that individual animal PK,
ultimately for use in the PK-PD model, be estimated in
animals without any blood samples taken during the PD
portion of the experiment. To this end, a series of simulations
was designed to evaluate the most parsimonious sampling
strategy from among a series of eight sampling scenarios (17,
18, 30). The population approach to the PK study design
allows the integrated application of PK samples from our
dense PK study with the sparser sampling planned for our PD
experiment. Through the application of nonlinear mixed
effects modeling utilizing a Bayesian approach, the dense
PK information can inform the PK model ﬁt for those
individuals with sparse sampling, allowing reconstruction of
a full PK time course projected during the PD experiment
(15, 31–34). Through examination of bias and precision of the
prediction errors for the PK and PD parameters from each of
the simulated sampling scenarios, the most parsimonious
sampling strategy was selected.
MATERIALS AND METHODS
Chemicals
Pregabalin, sildenaﬁl and the N-methyl metabolite of
sildenaﬁl were obtained from the Compound Control Unit of
Pﬁzer Global Research and Development, Pﬁzer UK.
Animals
Male Sprague-Dawley rats (200–250 g), obtained from
Charles River Laboratories (Margate,UK), were housed under
a 12:12 h light-dark cycle with food and water ad libitum.
Surgical Procedures
All experiments were conducted in a chronic constriction
rat model of neuropathic pain as previously described by
Bennett and Xie (35). Brieﬂy, this surgical procedure
involved tying four loose ligatures around the right sciatic
nerve. After this procedure, the animal developed a periph-
eral mononeuropathy which resembles the human condition
in its response to static and dynamic allodynia (35).
Jugular venous catheters (JVC) and carotid artery
catheters (CAC) were implanted according to standard
surgical procedures. Brieﬂy, this entailed making a small
incision in the skin over the right jugular vein or left carotid
artery and blunt dissection through the subcutaneous fat and
connective tissue to expose the vessel. A section of vessel
approximately 5 mm in length was then isolated, a loose
ligature was tied caudally and the cranial end was ligated. A
small incision was made between these ligatures, and the
catheter was introduced and secured in place with the
preplaced sutures. The catheter was then tunnelled subcuta-
neously to exit through the scapula region into a button of a
Dilab® automated blood sampling apparatus. A local ethics
review committee approved all experimental protocols.
Drug Administration and Blood Sampling
During this investigation, the PK of pregabalin was
determined in the presence of either a steady-state concen-
tration of sildenaﬁl, targeted at maximum target inhibition, or
placebo. Drugs were administered as an intravenous infusion
throughthejugular venous catheter. Volumes and infusionrates
were kept constant throughout all treatment groups. Sildenaﬁl
or placebo was administered by a combined bolus and
continued infusion. Speciﬁcally, a 1 mL/kg bolus containing
2 mg/kg sildenaﬁl was administeredover10 minsfollowed byan
infusion rate of 2 mL/kg/hr containing 12 mg/kg/hr of sildenaﬁl
for the duration of the planned 6 h PD experiment. Pregabalin
was administered as a 2-hr infusion (doses of 10 mg/kg/hr or
4mg/kg/hr),asthiswasdeterminedduringpilotstudiestobethe
optimal administration schedule. Speciﬁcally, this infusion
length allowed characterization of the PD endpoints during
both the upswing and downswing in concentration change
during the course of the 6-hr PD sampling planned for the
Fig. 1. Flowchart depicting PK modeling and the simulations
conducted in this study.
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the development of the PK model.
Blood samples were obtained with the use of a Dilab®
automated blood sampling apparatus. The Dilab® sampler
obtained blood samples of 200 μL through the carotid artery
catheter into heparinized containers. After blood sampling,
samples were centrifuged at 3,000 rpm for 3 mins, and plasma
was separated for storage at −20°C until analysis.
Pharmacokinetic Study Design
The PK study was designed as a crossover study on two
occasions with a washout between occasions as outlined in
Table I. A total of 28 rats divided evenly (n=7) among four
treatment groups were evaluated. The purpose of this multi-
day study was to allow independent estimation of the intra-
individual and the intra-occasion variability as well as to
conserve animals.
PK sampling was conducted in a staggered population
approach using seven different sampling schedules corre-
sponding to one rat from each of the four treatment groups
(Table II). Up to eight PK samples were taken from each
animal between 0.33–22 h after the start of the infusion on a
particular experimental day (Table II). Each rat was sampled
on day 1 and with at least a three-day washout period (day 4).
An optimal sampling algorithm (D-optimal) was utilized as
implemented in the ADAPT II software (36) to aid in the
selection of these time points.
Drug Analysis
Plasma samples were analyzed for quantiﬁcation of
pregabalin, sildenaﬁl and the major active N-methyl metab-
olite of sildenaﬁl by an LC-MS/MS method brieﬂy described
below.
The extraction of pregabalin, sildenaﬁl and the N-methyl
metabolite was performed using solid phase extraction. Rat
plasma samples, standards and quality controls (50 μL) were
mixed with 450 μL water and then 500 μL 1 M mono
chloroacetic acid in methanol/water (1:9 v/v)p r i o rt o
extraction using activated (2 ml methanol) solid-phase
extraction sorbent (Oasis MCX, Waters Corporation) packed
in a 96 well format with 30 mg sorbent per 2 ml well.
Following sample application, the cartridges were washed
sequentially with 1 ml water followed by 1 ml of 1 M mono
chloroacetic acid in methanol/water (1:9 v/v) followed by 1 ml
methanol. Pregabalin, sildenaﬁl and the N-methyl metabolite
and internal standards (UK-464,243 and UK-343,664) were
eluted with 1 ml of ammonium hydroxide:methanol (5:95 v/v)
into 2 ml deep, 96 well blocks. These extracts were retained in
the blocks, evaporated to dryness under a nitrogen stream
(37°C) and resuspended in 200 μL 2 mM ammonium acetate,
pH 4.0, in methanol water (10:90 v/v).
Samples were analyzed on a Sciex API 3,000 mass
spectrometer in positive mode using turbo ionspray. A fast
gradientHPLCwasusedwithaChromolithSpeedRodRP-18e,
50×4.6 mm, 5 μm (Merck) at 3 ml/min with ﬂow splitting ratio 1
to 5. Mobile phases of 0.027% HCOOH v/v +1 0m M
ammoniumacetate 90:10 water:CH3OH (organicmobilephase)
and 0.027% HCOOH v/v + 10 mM ammonium acetate 90:10
CH3OH:water (aqueous mobile phase)wereused and prepared
fresh on each day. The method scanned for all compounds
simultaneously. The MRM transitions used for each compound
were as follows: pregabalin (160 to 142); UK-464,242 (184 to
107); sildenaﬁl (475 to 58); the N-methyl metabolite of sildenaﬁl
(461 to 283); and UK-343,664 (566 to 346).
Intra- and inter-day assay accuracy and precision were
assessed for each compound at 150, 2,000, 9,000 ng/ml for
pregabalin and 3,500, 1,800 ng/ml for sildenaﬁl and UK-
103,302 spanning the calibration range (n=5). Accuracy was
assessed based upon the percentage of the ratio of the found
concentration on the nominal concentration. Intra-day assay
accuracies ranged from 95.5% to 107.6% for pregabalin,
Table I. Study Design for the PK Investigations. Four Groups of Seven Rats each were Administered Either Pregabalin and Saline or
Pregabalin and Sildenaﬁl on Two Separate Days as Described Above
Day 1 Day 4
Group 1 CCI rats pregabalin infusions with saline
Group 1A 7 rats 2 h pregabalin infusion at 4 mg/kg/hr 2 h pregabalin infusion at 10 mg/kg/hr
Saline loading dose and continuous infusion Saline loading dose and continuous infusion
Group 1B 7 rats 2 h pregabalin infusion at 10 mg/kg/hr 2 h pregabalin infusion at 4 mg/kg/hr
Saline loading dose and continuous infusion Saline loading dose and continuous infusion
Group 2 CCI rats pregabalin infusions with sildenaﬁl
Group 2A 7 rats 2 h pregabalin infusion at 4 mg/kg/hr 2 h pregabalin infusion at 10 mg/kg/hr
Sildenaﬁl 2.2 mg loading dose and 12 mg/kg/hr
continuous infusion
Sildenaﬁl 2.2 mg loading dose and 12 mg/kg/hr
continuous infusion
Group 2B 7 rats 2 h pregabalin infusion at 10 mg/kg/hr 2 h pregabalin infusion at 4 mg/kg/hr
Sildenaﬁl 2.2 mg loading dose and 12 mg/kg/hr
continuous infusion
Sildenaﬁl 2.2 mg loading dose and 12 mg/kg/hr
continuous infusion
Table II. Sample Times for Individual Rats During the PK Study.
Animal Number 1–7 Corresponds to Rat 1–7 in Each of the Four
Treatment Groups
Animal number Sample times (hrs)
1 0.33, 1.33, 2.33, 3.5, 5.5, 7.5, 12, 22
2 0.33, 1.33, 2.33, 4.5, 8.5, 12.5, 17, 22
3 0.66, 1.66, 2.5, 4, 8, 11.5, 16, 22
4 0.66, 1.66, 2.5, 5, 9, 11, 15, 22
5 1, 2, 3, 4.5, 8, 12, 16, 22
6 1, 2, 3, 5, 9, 12.5, 17, 22
7 1, 2, 3.5, 5.5, 9.5, 12.5, 16, 22
2261 Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats101.2% to 111.1% for sildenaﬁl and 99.8% to 107.2% for N-
methyl metabolite of sildenaﬁl. Inter-day (3 days) assay
accuracies ranged from 101.2% to 108.3% for pregabalin,
101.2% to 108.3% for sildenaﬁl and 100.0% to 102.8% for
UK-103,320. Precision of the assay was expressed as %CV
(coefﬁcient of variability) calculated from ﬁve replicates at
three concentrations. %CV for intra-day assay was 10.1
(150 ng/ml), 7.3 (2,000 ng/ml), 5.5 (9,000 ng/ml) for pregaba-
lin, 10.7 (3 ng/ml), 5.1 (500 ng/ml), 9.6 (1,800 ng/ml) for
sildenaﬁl, and 11.3 (3 ng/ml), 5.4 (500 ng/ml), 8.4
(1,800 ng/ml) for UK-103,320. %CV for inter-day assay was
13.2 (150 ng/ml), 10.2 (2,000 ng/ml), 11.6 (9,000 ng/ml) for
pregabalin, 14.5 (3 ng/ml), 5.3 (500 ng/ml), 7.8 (1,800 ng/ml)
for sildenaﬁl, and 13.8 (3 ng/ml), 6.6 (500 ng/ml), 9.0
(1,800 ng/ml) for UK-103,320. Quantitation was linear over
the following concentration ranges: pregabalin (100–10,000 ng/
ml), sildenaﬁl( 3 –2,000 ng/ml) and the N-methyl metabolite of
sildenaﬁl( 5 –2,000 ng/ml). The lower limit of quantitation for
pregabalin, sildenaﬁl, and the N-methyl metabolite of sildenaﬁl
was 70 ng/ml, 1 ng/ml, and 1 ng/ml, respectively.
Data Analysis
All PK modeling was accomplished utilizing a standard
nonlinear mixed effects approach implemented within NON-
MEM (double precision Version 5, level 1.1, GloboMax,
Hanover, MD) (37, 38). The models consisted of a structural
model that described the disposition of the drug following IV
administration, and a pharmacostatistical model that de-
scribed the between-subject, between-occasion and residual
variability. Diagnostic graphics, exploratory analyses, and
post-processing of NONMEM outputs were performed using
S-PLUS (Version 7.0 for windows, Insightful, Seattle, WA)
with a NONMEM interface developed by LAP&P consul-
tants BV (Leiden, the Netherlands).
The ﬁrst order conditional estimation method (FOCE-
INTER) was used for model building. The adequacy of each
model was assessed using standard goodness-of-ﬁt plots, the
precision of the parameter estimates (as calculated using the
COVARIANCE option of NONMEM) and the NONMEM
objective function value (OFV). When discriminating be-
tween hierarchical models based on OFV, the likelihood
ratio test was applied. This test is based on the property that
the ratio of the NONMEM objective function values (OFV)
(-2 log-likelihood) were asymptotically χ
2 distributed. An
objective function decrease of 10.8 units was considered
signiﬁcant (χ
2 p<0.001 df =1).
Standard errors for all parameters were obtained using the
covariance option in NONMEM. The population PK analysis
was performed using the NONMEM subroutine ADVAN 3
TRANS 4 (two-compartment model). It was assumed that both
the between-occasion variability (BOV) and the between-
subject variability (BSV) of the PK parameters were log-
normally distributed. Therefore, the relationship between a
PK parameter (P) and its variance was expressed as:
Pi ¼ PTV   e  BSVPþ BOVP ðÞ ð1Þ
Here, Pi was the value of PK parameter for the i
th individual,
PTV was the typical value of P for the population, and
(ηBSVP+ηBOVP) denoted the difference between Pi and PTV,
independently, which was identically distributed with a mean
of zero and variance of ωP
2. ηBSVrefers to the between-subject
variability, while ηBOV is the between-occasion variability.
The residual variability was examined using additive,
proportional,andcombinederrorstructuresasdescribedbelow:
Additive error : yij ¼ b yij þ "ij ð2Þ
Proportional error : yij ¼ b yij 1 þ "ij
  
ð3Þ
Combined additive and proportionalerror :
yij ¼ b yij 1 þ "ij
  
þ "ij
0 ð4Þ
Here, yij was the j
th observation in the i
th individual, ^ yij
was the corresponding model prediction, and εij (or "
0
ij ) was a
normally distributed random error with a mean of zero and a
variance of σ
2.
The ﬁnal model was developed by testing the effect
of subject-speciﬁc covariates’ bodyweight, age, time post
CCI-surgery, time post catheterization surgery, sildenaﬁl
concentration, and sildenaﬁl’s metabolite concentration. All
covariates were initially modeled as continuous. Sildenaﬁl
was also modeled as a discrete covariate as the steady state
infusions used during the PK study resulted in a relatively
stable concentration of sildenaﬁl which would saturate its
target over the experimental period of interest. Stepwise
covariate selection was utilized for the covariate model-
building (39–43). First, exploratory covariate selection was
performed by examination of the normalized eta deviation
between individual post-hoc parameter estimates and candidate
covariates. Subsequently, various forms of parameterization of
the selected covariates were added to the base model and
evaluated for signiﬁcance by observing ΔOFV and diagnostic
plots. Only the single covariate parameterization producing the
most signiﬁcant increase in goodness ofﬁt then moved on to the
next stage. This continued until no signiﬁcant improvements in
model ﬁt could be gained through further covariate inclusion.
The following example shows the effect of a continuous
covariate on CL:
TVCL ¼  CL   Cov=MedCov ðÞ
 Cov ð5Þ
CL ¼ TVCL   exp  i ðÞ ð 6Þ
TVCL was the typical value for the population; ηi was the
random effect representing the difference of the i
th subject from
the population mean. The random effects of between-subject
variability were assumed log-normally distributed, with a mean
of zero and standard deviation of ω. Cov was the continuous
covariate that was affecting CL,a n dMedCov was the median
Cov. The following example shows the effect of a discrete
covariate sildenaﬁl presence (SLDB) on CL:
TVCL ¼  CL þ 1   SLDB ðÞ    SLD ð7Þ
When SLDB was 0 (sildenaﬁl absence = 0, sildenaﬁl
presence = 1), TVCL equals θCL and when SLDB was 1, the
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CL. The ﬁnal model was evaluated utilizing bootstrapping
with resampling technique to examine the stability of the ﬁnal
model and estimate conﬁdence intervals of the parameters
(44–46). This technique consists of ﬁtting the model to 100
bootstrapped replicates of the dataset using the bootstrap
option in the LAP&P software interface for SPLUS. Param-
eter estimates for each of the replicate data sets were
obtained. The results from 500 successful runs were obtained,
and the mean and 2.5th and 97.5th percentiles (denoting the
95% conﬁdence interval) for the population parameters were
determined and compared with the estimates of the original
data.
A posterior predictive check was performed (47). A
posterior predictive check involves utilizing the simulation
option within NONMEM to create 90% prediction bands.
These are obtained by simulating 1,000 replications using the
ﬁnal model and a dataset including identical experimental
design. For each observation, the values of the 51st highest
and the 51st lowest prediction become the edges of the 90%
prediction band. Observed values are then plotted on the
same scale as these bands to help visualize the adequacy of
model ﬁt. After completion of these steps, the ﬁnal descrip-
tive PK-PD model was proposed.
Simulations to Evaluate Pharmacokinetic Sampling
Paradigms
The population PK model was used as the basis of
simulations designed to identify the most parsimonious PK
sampling schedule for implementation in the future PK-PD
study. The simulation study design was selected to mimic the
pregabalin-only portion of the planned PD study. Doses and
number of animals per group were previously determined
from pilot experiments based on the nature of the PD
interaction and what could be realistically utilized in these
types of experiments, respectively. As such, the motivation
for the simulation PK study was intended only to optimize the
PK sampling portion of future PD experiments.
PK proﬁles for pregabalin doses of 4 and 10 mg/kg/hr
were simulated with 12 rats in each dose group for each
sampling scenario. Simulated samples were generated from
these proﬁles according to the sampling schedule. A total of
eight sampling scenarios were examined as outlined in
Table III. Next, the simulated samples were combined back
with the real-world PK samples to serve as an anchor for the
population PK model. These new datasets were then remod-
eled, and the newly predicted individual PK parameters were
compared with those used to create the simulation. Prediction
errors were then calculated to determine the bias and
precision of predictions provided through each sampling
scenario. After this evaluation process was completed for
the PK model, a PD model examining the impact of the
various PK sampling schedules on the ability to predict PD
was evaluated in a similar fashion. More detailed methods are
described below.
Sampling scenarios to be evaluated (Table III) were
selected to compare various post-PD sampling schedules with
the best case (eight PK samples) and worst case (no samples)
scenarios. In addition, a sampling design with only a single
PK sample taken during the PD portion of the experiment
was simulated. The ﬁrst four scenarios included only post-PD
sampling. The ﬁfth scenario examined the effects of dense
sampling during the entire experiment, but on another
occasion. The sixth schedule examined the hypothetical
best-case scenario of dense sampling during the entire
experiment (were it possible). The seventh scenario examined
the potential beneﬁt of including one sample during the PD
experiment and one immediately after. Finally, the worst case
scenario of obtaining no individual animal PK was assessed.
Monte-Carlo simulations were used to examine the
impact of the various sampling schedules on the identiﬁcation
of the individual animal-speciﬁc PK. In this procedure the
simulation function of NONMEM creates “simulated rats.”
These simulated rats have PK parameters (simulated param-
eters) selected from within the distribution of possible
parameters deﬁned by the ﬁnal PK model with the assistance
of a random number generator. Simulated PK proﬁles were
then generated for each of the simulated rats with samples
taken from each of these proﬁles according to the proposed
sampling schedule. These simulated concentration points
were then combined with the complete PK dataset (real
dataset from the dense PK study), along with the “true”
individual-speciﬁc simulated parameter estimates (for future
comparison). This new simulated dataset was modeled in
NONMEM utilizing the same methods as described in the PK
analysis section generating predicted parameters. This whole
process is outlined in Fig. 1.
This cycle of simulation and estimation was repeated 100
times for each of the eight sampling schedules creating 100
“simulated experiments” for each. Model performance was
then assessed examining how close the predicted parameters
were to the “true” or simulated parameters using the
prediction error on the individual clearance parameter
estimates. The prediction error (PE) was calculated as
follows:
PE ¼
 pred    sim
 sim
  100% ð8Þ
The prediction errors were visualized for each sampling
schedule using boxplots to examine their bias (median predic-
tion error) as well as precision (quartiles) for each replication.
The bias and precision along with practical considerations
served to guide the sampling protocol selection.
A previously developed PK-PD model was then applied
to examine the ability to accurately identify the EC50 for
static allodynia given three sampling scenarios (best(6), worst
Table III. Sampling Scenarios and the Corresponding Sampling
Times Investigated for Proposed Downstream PK-PD Studies. PD
Sampling Duration was Treated as Lasting 6 h Following the Start of
a 2-hr Pregabalin Administration
Sampling scenario Sample times (hr)
16
2 6,8
3 6,8,24
4 6,8,10,12,15,18,21,24
5 1,2,4,6,8,12,18,24 (another occasion)
6 1,2,4,6,8,12,18,24
7 2,6
8 No sampling
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described above was applied. This was coupled with an effect
comparment, which was used to drive the PD model. The PD
model consisted of a sigmoid EMAX model to relate the
concentration of drug available at the effect site (Ce(t)) to the
observed response expressed as a percentage change in
response to static allodynia from baseline. In this model,
EMAX is the maximum change in response the drug can
produce (ﬁxed to 1 or 100%), EC50 is the value of Ce(t)
producing 50% of the EMAX value, and Hill inﬂuences the
steepness of the relationship:
EðtÞ¼
EMAX   CeðtÞ
Hill
EC50
Hill þ CeðtÞ
Hill ð9Þ
Parameters for the Emax model were obtained from a
pilot study in a chronic constriction injury model of neuro-
pathic pain, using the difference in paw withdrawal threshold
upon stimulation with von Frey hairs as a pharmacodynamic
endpoint (28). The study was conducted in male Sprague
Dawley rats (Charles River Laboratories (Margate,UK). The
values of the (population) pharmacodynamic parameters
were Keo = 6.27 h (23.6%), EC50 = 9.36 ug/mL (5.3%),
Emax = 1, and Hill = 3.8 (8.3%), assuming a normal
distribution. PD parameters and plots were simulated and
re-evaluated in NONMEM in the same way as the PK
simulations. From the simulated and predicted PD parame-
ters, prediction errors for EC50 were calculated and evaluat-
ed in the same way as the PK parameters and considered in
the selection of the most appropriate sampling strategy.
RESULTS
Concentrations of pregabalin, sildenaﬁl and the active
hydroxyl metabolite of sildenaﬁl are displayed in Fig. 2.
Maximal concentrations of pregabalin were reached at the
end of the 2-hr infusion and are roughly 22,000 and 10,000 ng/
mL respectively for the 10 mg/kg/hr and 4 mg/kg/hr pregaba-
lin infusions. When sildenaﬁl was administered concomitantly,
visible increases in the concentrations of pregabalin can be
observed.
A two-compartment model was chosen as the ﬁnal
structural model to describe the concentration time course
of pregabalin. Estimated model parameters are listed in
Table IV. Both between-subject variability and between-
occasion variability were determined in the base model for
clearance (BSV 0.024(24.7%), BOV 0.098(27.1%)) and the
volume of the central compartment (BSV 0.017(9.4%), BOV
0.015(9.0%)). A proportional error model was selected to
account for the residual variability. Overall diagnostic plots
demonstrated a good model ﬁt (Fig. 3). Observed values
versus both population and individual predicted were near
the line of identity. Weighted residuals were relatively small
in magnitude and randomly distributed when viewed versus
time and concentration.
Of all the covariates investigated, only sildenaﬁl and its
metabolite had a signiﬁcant impact on the model. This is
likely due to the homogeneous nature of the inbred rat strain
and controlled conditions of the experiment. Two ﬁnal
covariate models incorporating the presence of sildenaﬁl
were decided upon. First, a binary model was implemented
Fig. 2. Raw data concentration vs. time plots for: A a 2-h infusion of
pregabalin at 10 mg/kg/hr + saline, B for a 2-hr infusion of pregabalin
at 4 mg/kg/hr + saline and C sildenaﬁl and its active hydroxy
metabolite from Group 2 rats.
2264 Bender et al.Table IV. Objective Function Values (OFV) and Parameter Value Estimates for the Two-Compartment Pregabalin PK Model. Sildenaﬁl
Interaction was Incorporated as Either a Binary (1—SLDB)θSLD or Continuous (1-[SLDM]/(θSLD + [SLDM])) Covariate Effect on Clearance.
ω1 and ω2 Denote Between-Subject and Between-Occasion Variability, Respectively, for the Listed Model Parameter
Original PK Model Binary Sildenaﬁl Covariate Continuous Sildenaﬁl Metabolite Covariate
OFV 5405.6 5397.1 5363.0
Value CV% LLCI ULCI Value CV% LLCI ULCI Value CV% LLCI ULCI
CL (L/hr) 0.034 19.08% 0.021 0.046 0.052 14.59% 0.037 0.066 0.051 8.83% 0.042 0.060
V1 (L) 0.270 3.38% 0.252 0.288 0.271 3.38% 0.253 0.289 0.272 3.27% 0.255 0.289
Q (L/hr) 0.0225 32.00% 0.0084 0.0366 0.0151 35.76% 0.0045 0.0257 0.0229 18.08% 0.0148 0.0310
V2 (L) 6.75 41.48% 1.26 12.24 2.77 51.99% −0.05 5.59 2.45 38.82% 0.59 4.31
ω1CL 0.024 24.74% 0.012 0.035 0.017 15.91% 0.012 0.022 0.013 14.63% 0.009 0.016
ω1V1 0.017 9.38% 0.014 0.020 0.018 9.26% 0.014 0.021 0.016 8.72% 0.013 0.018
ω1Q 0.430 40.00% 0.093 0.767 0.439 40.87% 0.087 0.791 0.081 15.94% 0.055 0.106
ω2CL 0.098 27.07% 0.046 0.151 0.061 19.52% 0.038 0.085 0.071 18.52% 0.045 0.097
ω2V1 0.015 8.96% 0.013 0.018 0.015 8.75% 0.012 0.017 0.016 8.33% 0.013 0.019
θSLD –– ––0.302 23.05% 0.166 0.438 1350
(ng/mL)
28.37% 599 2101
σresidual 0.029 18.32% 0.019 0.040 0.029 18.53% 0.019 0.040 0.029 18.85% 0.018 0.039
Fig. 3. Diagnostic plots for the pregabalin PK model: A observed vs. individual predicted, B observed vs. population
predicted, C weighted residuals vs. time, D and weighted residuals vs. predicted pregabalin concentration. Symbols depict
data points from rats administered 4 mg/kg without sildenaﬁl (circles), 10 mg/kg without sildenaﬁl (squares), 4 mg/kg with
sildenaﬁl (+), and 10 mg/kg with sildenaﬁl (triangles).
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experiment. The ﬁnal parameters for this model are shown
in Table IV. The effect on clearance was demonstrated
graphically in Fig. 4. Sildenaﬁl resulted in a reduction in
pregabalin clearance of 30.2% with a CV of 23.1%. The
optimal descriptive model ﬁt utilizing the continuous concen-
trations of sildenaﬁl and its metabolite was also sought.
Various parameterizations of the effect of sildenaﬁl, sildena-
ﬁl’s metabolite, and combinations of the two were examined.
The parameterization identiﬁed as giving the largest increase
in goodness of ﬁt was a nonlinear function utilizing only the
plasma concentration of sildenaﬁl’s active metabolite
[SLDM]:
TVCL ¼  CL 1  
SLDM ½ 
 SLD þ SLDM ½ 
  
ð10Þ
Final parameter values for this model are listed in
Table IV. Bootstrapping with replacement demonstrated a
good model ﬁt, mean parameter values remained near the
ﬁnal model, and CV% was low. A posterior predictive check
also demonstrated a good model ﬁt. Fig. 5 demonstrates that
most of the observed data points fall within the 90%
prediction interval.
The resulting box-plot summaries for the PK-PD simu-
lation prediction errors on clearance and EC50 are illustrated
in Figs. 6 and 7, respectively. The ﬁrst four sampling scenarios
with post-PD sampling (6 h or later) demonstrated that
improved predictability of clearance occurred when more
post-PD samples were obtained. Notably, improvements in
both bias and precision were seen as the number of samples
increased. However, sampling scenario 4 with eight PK
samples was only slightly better than scenario 3 with only
three post-PD samples. Sampling on another occasion, even
with eight samples spaced throughout the experiment at
equivalent times to scenario 5, was no better than obtaining
no samples at all (comparable bias and precision for scenarios
5 and 8). Scenario 6 represented the hypothetical best-case
situation if dense blood samples were taken throughout the
experiment. The bias was negligible and the precision was the
tightest for this scenario; however, the bias was comparable
and the precision only slightly better than both scenarios 3
and 4. Adding a single sample during the PD portion of the
experiment (0–6 h) in scenario 7 was of no added value in
comparison with scenario 2 where two samples were taken
after the PD experiment. Finally, scenario 8 served as a point
of comparison where no PK samples were taken. As
expected, this produced the most imprecise estimates and
introduced the largest amount of prediction error, along with
scenario 5 where blood samples were taken in the same
animal, but on a separate occasion. There was no bias in this
schedule as the typical parameter values were assumed for all
individuals. PD simulations reﬂected these conclusions for the
three simulated sampling schedules.
DISCUSSION
The development of a PK model identifying a PK
interaction between pregabalin and sildenaﬁl in rats was
investigated. Furthermore, these results served to inform the
design of a future quantitative PD study examining the
interaction of these drugs. This PK study design also serves
as the ﬁrst step toward identifying and quantifying a
synergistic PD interaction between pregabalin and sildenaﬁl.
Fundamental to identifying the source for an observed
interaction between two compounds is to take the inﬂuence
of a potential PK interaction into account (14, 15). The results
of this analysis served that purpose by quantifying the PK of
pregabalin with and without the presence of sildenaﬁli nr a t s ,
notinga30.2%decreaseintheclearanceofpregabalinwhenco-
administered with sildenaﬁl. This decrease in clearance was
unexpected, and the mechanism for the PK interaction remains
unclear. One potential hypothesis to explain this interaction
m a yb ea ne f f e c to fs i l d e n a ﬁl on renal transporters affecting
pregabalin, although there is no information to enlighten this
theory. The decrease in pregabalin clearance did produce a
slight increase in the observed plasma concentrations of
pregabalin over the observation period of interest.
The effect of pregabalin on the PK of sildenaﬁl was not
investigated. N-methyl sildenaﬁl attained a Cmax of 2,100 ng/
mL at 4–7 h, compared to sildenaﬁl with a Cmax of 2,400 ng/
mL at 2–4 h. While the metabolite Cmax was slightly lower
Fig. 4. Scatter plots demonstrating the effect of sildenaﬁl administration on clearance: A pregabalin clearance vs. a binary
variable representing either no sildenaﬁl (0) or with sildenaﬁl (1) and B pregabalin clearance vs. the concentration of
sildenaﬁl’s metabolite.
2266 Bender et al.Fig. 7. Box plot summaries of prediction errors on EC50 for three of
the eight sampling schedule scenarios: 3. (6, 8, and 24 h), 6. (1, 2, 4, 6,
8, 12, 18, and 24 h), and 8. no PK samples.
Fig. 6. Box plot summaries of prediction errors on clearance for each
of the eight sampling schedule scenarios: 1. (6 h), 2. (6 and 8 h), 3. (6,
8, and 24 h), 4. (6, 8, 10, 12, 15, 18, 21, and 24 h), 5. (another occasion:
1, 2, 4, 6, 8, 12, 18, and 24 h), 6. (1, 2, 4, 6, 8, 12, 18, and 24 h), 7. (2
and 6 h), and 8. no PK samples.
Fig. 5. Posterior predictive check of pregabalin concentration vs. time proﬁles for each of the treatment groups
administered a 2-hr pregabalin infusion at: A 4 mg/kg/hr without sildenaﬁl, B 10 mg/kg/hr without sildenaﬁl, C 4 mg/kg/
hr with sildenaﬁl, and D 10 mg/kg/hr with sildenaﬁl. Lines represent the 90% prediction interval for the model.
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was much higher than that observed for the metabolite and
parent in humans (0.4) (48). While the higher ratio may
inﬂuence model development and subsequent human scale-
up for non-saturating doses of sildenaﬁl, the bolus and
maintenance dose selected within this study attained a
saturable plasma concentration of sildenaﬁl for the PDE-5
receptor (>>3.5 nM) at all time points (49). As concentrations
of sildenaﬁl that would saturate the PDE-5 enzyme were
attained, any minor impact of pregabalin on the PK of
sildenaﬁl would be negligible in this study design.
An additional objective was to determine a PK sampling
strategy sufﬁcient for representing actual rat PK proﬁles
during future planned PD experiments. Capturing individual
PK would not be straight-forward, as blood sampling during
the PD experiment could lead to an introduction of PD
measurement errors. For this reason, simulations provide an
ideal platform for evaluating multiple limited sampling
strategies for describing individual PK (17, 44, 50). Further-
more, this type of preclinical trial simulation allows efﬁcient
examinations of multiple experimental scenarios before any
animals are utilized, ensuring that experimental animals are
utilized in the most effective manner possible.
A total of eight sampling scenarios were examined by
combining PK experimental data with simulated rat pregaba-
lin plasma concentrations based on the above developed
pregabalin PK model. Sampling strategy success was then
assessed by comparing the PE of the predicted clearance to
the actual (combined experimental and simulated data set)
population clearance. Sampling the same rats on another
occasion was determined to be of no added value compared
to taking no blood samples at all due to the large degree of
intra-individual and inter-occasion variability identiﬁed in this
PK model for the volume (0.015(9.0%)) and clearance (0.098
(27.1)%). PK predictions using no blood samples from any of
the rats produced no bias in the estimates of clearance, but it
introduced a lack of precision in estimating individual PK.
Optimally, taking eight blood samples spaced during and after
the experiment produced the lowest bias and highest
precision in the prediction errors.
Sampling in this optimal fashion described above served
only as a benchmark, since collecting blood samples during
the PD experiment would confound the PD experimental
results. For this reason, additional sampling strategies involv-
ing a varying number of post-PD samples were also exam-
ined. Collecting one post-PD blood sample offered a small
improvement in precision over no blood sampling, but it also
introduced bias into the prediction errors. Increasing the
number of post-PD samples reduced this bias and improved
the precision; however, the degree of improvement in both
bias and precision diminished with increasing blood samples.
Increasing from three to eight post-PD samples slightly
improved prediction error precision, but it was decided that
these improvements in precision were not sufﬁcient to
warrant the collection of ﬁve additional samples due to the
resulting blood volume alterations, animal stress, and
research costs. Thus, collecting three post-PD blood samples
was deemed sufﬁcient for removing bias in the prediction
error and drastically improving the precision.
Static allodynia PD simulations supported this conclusion
by demonstrating that the three-sample schedule provided
increased precision in estimating EC50s compared to taking
no blood samples, and was only marginally worse than the
unrealistic best-case scenario of eight samples taken during
and after the PD experiment. This increased precision in
identifying individual EC50s will allow a greater ability to
identify changes in potency when examining the interaction
between these two compounds. Furthermore, these types of
simulations may also serve as an example for other preclinical
studies to help reﬁne experimental design.
Overall, this study developed a two-compartment model
capable of accurately describing pregabalin PK in the
presence or absence of sildenaﬁl. These results also served
to inform the sampling schedule design for future quantitative
PK-PD study examining the interaction of these two drugs.
Finally, this PK study also served as an initial step towards
identifying and quantifying potential PK and PD interactions
between pregabalin and sildenaﬁl.
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